Evidence map›Paper›PMID 41601174›Full record

ReviewCurrent vascular pharmacology2025

Roles of Empagliflozin in Diabetic Cardiomyopathy: A Review.

Hao Luo, Ningzhi Zhang, Yingying Liu, Chen Pei, Pinglin Duan, Xiaokun Lou, Huan Yu, Qingqing Lei, Gangfeng Zhao, Mingwei Wang and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current vascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hao LuoDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Ningzhi ZhangDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Yingying LiuDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Chen PeiDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Pinglin DuanDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Xiaokun LouDepartment of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Huan YuDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Qingqing LeiDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Gangfeng ZhaoDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Mingwei WangDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Qibin JiaoDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Wenyan GongDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.ORCID 0000-0001-6950-7545
Xingwei ZhangDepartment of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.

Funding

General project of Hangzhou Health Science and Technology Plan A20240135Zhejiang Provincial Natural Science Foundation of China LY24H310005
6 · The paper itself

Abstract

Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), represents a novel therapeutic agent for diabetes management. Over the past decade, studies have consistently demonstrated that EMPA not only effectively lowers blood glucose levels but also confers substantial cardiovascular benefits without inducing hypoglycemia. This holds for individuals with or without diabetes, highlighting EMPA's potential in mitigating the risk of adverse cardiovascular events and cardiovascular mortality. The underlying mechanisms driving these advantageous effects remain incompletely understood, with presently elucidated pathways encompassing blood pressure reduction, oxidative stress attenuation, anti-inflammatory properties, metabolic regulation, uric acid level modulation, inhibition of Na+/H+ exchangers, preservation of mitochondrial function, vascular protection, and regulation of myocardial autophagy. In this review, we considered the effects and mechanisms of EMPA in combating diabetic cardiomyopathy (DCM), underscoring its therapeutic relevance in addressing cardiovascular complications associated with diabetes.

Indexed as

Benzhydryl CompoundsBlood GlucoseDiabetes Mellitus, Type 2Diabetic CardiomyopathiesGlucosidesSodium-Glucose Transporter 2 InhibitorsAnimalsHumansOxidative StressTreatment OutcomeBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitorsdiabetic cardiomyopathyEmpagliflozinmyocardial protection.Reactive oxygen speciesSGLT2SGLT2i

Identifiers

PMID41601174

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.